Group 1 - Company shares of 基石药业-B (02616) increased by over 5%, reaching a price of 6.07 HKD with a trading volume of 22.7042 million HKD [1] - The company announced that its RET inhibitor, 普吉华 (普拉替尼胶囊, 100mg), has been successfully included in the latest National Medical Insurance Catalog, effective from January 1, 2026 [1] - To date, 基石药业 has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national insurance catalog [1] Group 2 - Tianfeng Securities published a report in August, predicting that the inclusion of 普拉替尼 in the insurance catalog is expected to accelerate its market penetration [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] - The innovative internal ADC technology platform of the company features optimized proprietary linkers to improve the selective release of effective payloads in tumors, supporting multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for future development [1]

Group 1 - The stock of Basilea Pharmaceutica Ltd. (02616) increased by over 8%, reaching HKD 8.74 with a trading volume of HKD 11.72 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basilea by acquiring 80.4 million shares at an average price of HKD 7.90 per share, totaling approximately HKD 635 million, resulting in a new holding of 5.49% [1] - Basilea reported a significant decline in revenue for the first half of the year, amounting to RMB 49.45 million, a decrease of 80.54% year-on-year, while R&D expenses rose by 58.75% to RMB 105 million, leading to a loss of RMB 270 million [1] Group 2 - Basilea's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [2] - The company has developed an innovative internal ADC technology platform that enhances the release of payloads selectively targeting tumors, supporting multiple ADC products in its pipeline [2] - The platform is expected to provide ongoing momentum for the company's future development [2]